BEAM Beam Therapeutics Inc.
24.77USD-1.82%Mkt Cap: 2.56B $P/E: —1d ago
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap2.56B USD
Enterprise Value1.62B USD
Revenue (TTM)156.04M USD
Gross Profit-252.63M USD
Net Income (TTM)-79.99M USD
Revenue/Share1.51 USD
Last Price24.77 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees540
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.32
PEG—
EV/EBITDA-4.54
EV/Revenue10.35
P/S16.70
P/B2.36
EPS (TTM)-0.68
EPS (Forward)-4.74
52W Range
20.2325% of range38.26
52W High38.26 USD
52W Low20.23 USD
Profitability
Gross Margin-161.91%
Oper. Margin-25827.14%
EBITDA Margin-228.01%
Profit Margin-57.24%
ROE-6.46%
ROA-5.40%
Growth
Revenue Growth-94.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-345.10M USD
CapEx (TTM)14.95M USD
FCF Margin-154.99%
FCF Yield-9.45%
Net Debt-905.57M USD
Net Debt/EBITDA2.55
Balance Sheet
Debt/Equity0.12
Current Ratio14.57
Quick Ratio14.25
Book Value/Sh10.69 USD
Cash/Share11.54 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)52.15 USD
Upside (mean)+110.6%
Target Range26.00 USD – 80.00 USD
26.00+110.6% to mean80.00
# Analysts13
Ownership
Shares Out.103.29M
Float88.33M
Insiders1.20%
Institutions107.92%
Short Interest
Short Ratio13.5d
Short % Float38.75%
Short % Out.25.06%
Shares Short25.88M
Short (prev mo.)24.37M
Technical
SMA 5026.59 (-6.8%)
SMA 20028.47 (-13.0%)
Beta2.20
S&P 52W Chg16.45%
Avg Vol (30d)1.89M
Avg Vol (10d)1.70M
Technical Indicators
RSI (14)44.7
MACD-0.6312
MACD Signal-0.7958
MACD Hist.+0.1645
BB Upper26.32 USD
BB Middle24.75 USD
BB Lower23.17 USD
BB Width12.70%
ATR (14)1.466 USD
Vol Ratio (20d)1.17x